Kadence Bio

Kadence Bio (www.kadencebio.com) is a clinical stage therapeutics company developing the first FDA-approved treatment for premature ejaculation (male climax control). The first-in-class treatment aims to bridge the ‘intimacy gap’: ~3x difference in average time to climax between healthy men and women, contributing to 75% of women not reaching climax during intercourse. The difference is increased to ~10x in couples with premature ejaculation. Improving climax control also helps with reproductive potential and overall well-being. There is currently no treatment approved by the FDA to treat the condition, which affects up to 20% of men and their partners worldwide. The goal is to do for premature ejaculation what Viagra did to revolutionize the treatment of erectile dysfunction. We obtained regulatory approvals to enter the clinic in 2023 (US IND, UK CTA). We completed dosing in our Phase 1 first-in-human trial assessing the safety and pharmacokinetics of our lead product, with great results. We plan to initiate our first Phase 2 efficacy study in H2 2025. Pipeline compounds at the discovery stage focus on acute mood disorders. The team includes repeat founders (former Nasdaq IPOs: CMPS, ATAI) and senior pharma executives (including the current global Chief Medical Officer at GSK and the former head of sales and marketing for Viagra at Pfizer).